[The medical treatment strategy of secondary hyperparathyroidism use of vitamin D in Europe and America]

Clin Calcium. 2004 Sep;14(9):57-9.
[Article in Japanese]

Abstract

The medical treatment strategies of vitamin D appeared in the guideline of K/DOQI (Kidney Disease Outcomes Quality Initiative) in the U.S. and Clinical algorithms on renal osteodystrophy in Europe. The target intact PTH value is 150-300 pg/mL (16.5-33.0 pmol/L) in U.S. and 9-18 pmol/L (82-164 pg/mL ) in Europe. It was set up more highly in U.S. than in Europe. A European and American medical treatment strategies are not so different from that of Japan in the routes and metabolites of vitamin Ds.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Biomarkers / blood
  • Chronic Kidney Disease-Mineral and Bone Disorder / complications
  • Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy
  • Europe
  • Humans
  • Hyperparathyroidism, Secondary / diagnosis
  • Hyperparathyroidism, Secondary / drug therapy*
  • Hyperparathyroidism, Secondary / etiology
  • Parathyroid Hormone / blood
  • Practice Guidelines as Topic*
  • United States
  • Vitamin D / administration & dosage*
  • Vitamin D / analogs & derivatives

Substances

  • Biomarkers
  • Parathyroid Hormone
  • Vitamin D